Director, Corporate Development & Strategy
Superluminal Medicines, Inc.
Summary
Superluminal Medicines is seeking a Director, Corporate Development and Strategy to support the strategic evaluation and advancement of the company's drug discovery and development portfolio. Reporting to the SVP, Business Development & Operations, this individual will play a critical role in evaluating the commercial feasibility and strategic potential of pipeline programs, informing investment decisions, and supporting corporate development and business planning initiatives. Working cross-functionally with leaders across Research, Development, Business Development and Finance, the Director will translate scientific opportunities into commercial and business insights, assess market opportunities and competitive dynamics, and develop strategic analyses to support informed decision-making.
Job description
About the Role
Superluminal Medicines is seeking a Director, Corporate Development and Strategy to support the strategic evaluation and advancement of the company's drug discovery and development portfolio. Reporting to the SVP, Business Development & Operations, this individual will play a critical role in evaluating the commercial feasibility and strategic potential of pipeline programs, informing investment decisions, and supporting corporate development and business planning initiatives. Working cross-functionally with leaders across Research, Development, Business Development and Finance, the Director will translate scientific opportunities into commercial and business insights, assess market opportunities and competitive dynamics, and develop strategic analyses to support informed decision-making.
Key Responsibilities
New Product Planning and Competitive Intelligence
- Define unmet need for each program through landscape assessments, treatment-paradigm analysis, KOL and payer input, and primary and secondary market research.
- Assess commercial opportunities, and build revenue forecasts and scenarios by target patient populations, segments, and geographies.
- Build and maintain comprehensive competitive landscapes for each program: track and prioritize competitor programs, identify upcoming data readouts or regulatory events, and flag implications for our programs.
- Identify commercial risks, differentiation opportunities and key value drivers that may influence asset development and strategic decisions.
- Partner with program leads to translate unmet needs and competitive benchmarks into competitive TPPs, and use them to inform development plans, indication selection and sequencing, trial design, and go/no-go criteria.
- Engage external consultants, market research providers and industry experts, as appropriate, to support commercial assessments.
Portfolio Strategy & Business Planning
- Support the development and ongoing refinement of Superluminal's enterprise strategy, strategic priorities, portfolio plan, and long-range plan.
- Partner with scientific and functional leadership to develop and maintain a strategic view of the company's portfolio, including key milestones, risks, and opportunities.
- Work cross functionally to establish annual and multi-year business plans, ensuring alignment between corporate objectives, portfolio priorities and functional strategies.
- Develop business cases, financial analyses and scenario models to evaluate strategic alternatives, investment requirements and potential returns.
- Create clear decision frameworks for resource allocation, sequencing, partnering, financing, and organizational investment.
Corporate and Business Development
- Support Executive Committee and Board-level discussions on portfolio strategy, investment priorities and long-term value creation.
- Synthesize complex scientific, commercial and financial information into clear, actionable recommendations.
- Develop executive-level presentations, analyses and recommendations for leadership and Board discussions.
- Provide strategic and analytical support for business development opportunities, including potential partnerships, licensing and external asset evaluations.
- Create partner facing materials that connect platform advantages and program progress to collaboration and licensing opportunities.
- Develop and maintain investor presentations, the corporate narrative, Q&A, and diligence materials that connect scientific progress to enterprise value.
Minimum Qualifications
- Bachelor's degree in Life Sciences, Business, Finance, Economics or a related discipline.
- 8+ years of relevant experience in biotechnology or pharmaceuticals, with a background in commercial strategy, portfolio strategy, corporate development, business development, venture capital or life sciences management consulting.
- Experience within an emerging or early-stage biotechnology company.
- Experience conducting commercial feasibility assessments, market opportunity evaluations, competitive analyses and strategic assessments of drug development programs or pipeline assets.
- Experience in drug discovery and development lifecycle, particularly early-stage development, and the ability to evaluate commercial opportunities in the context of evolving scientific and clinical data.
- Experience developing commercial assumptions, market models, financial analyses, business cases and scenario assessments to support strategic and investment decisions.
- Experience routinely briefing C-suite, Board members, or operating committee stakeholders on a regular cadence.
- Experience authoring and presenting cross functional business cases and assessments that integrate clinical, financial, and regulatory data to drive go/no-go decisions.
- Experience collaborating with scientific, commercial, finance and executive leadership teams.
Preferred Qualifications
- Master's degree, PhD, or equivalent practical experience preferred.
- Direct experience structuring, negotiating, or drafting corporate development or partnering transactions within the biotechnology or pharmaceutical sector (e.g., licensing, asset acquisitions, or strategic alliances).
Requirements
- Bachelor's degree in Life Sciences, Business, Finance, Economics or a related discipline
- 8+ years of relevant experience in biotechnology or pharmaceuticals
- Background in commercial strategy, portfolio strategy, corporate development, business development, venture capital or life sciences management consulting
- Experience within an emerging or early-stage biotechnology company
- Experience conducting commercial feasibility assessments, market opportunity evaluations, competitive analyses and strategic assessments of drug development programs or pipeline assets
- Experience in drug discovery and development lifecycle, particularly early-stage development
- Experience developing commercial assumptions, market models, financial analyses, business cases and scenario assessments
- Experience routinely briefing C-suite, Board members, or operating committee stakeholders
- Experience authoring and presenting cross functional business cases and assessments integrating clinical, financial, and regulatory data
- Experience collaborating with scientific, commercial, finance and executive leadership teams
Benefits
- Medical, Dental & Vision
- 401(k) Matching
- Transportation Subsidy
- Equity
- Unlimited PTO
- Disability Insurance
- Life Insurance
Company overview
Superluminal Medicines, Inc. is a Boston-based generative biology and chemistry company revolutionizing drug discovery through the integration of artificial intelligence, machine learning, and structural biology. Founded in 2022, the company has developed its proprietary Hyperloop™ Platform that combines cutting-edge structure-based drug discovery with AI-powered computational methods and experimental validation to rapidly identify and develop small molecule therapeutics. The company focuses on historically challenging membrane receptor targets, particularly G protein-coupled receptors (GPCRs), which represent approximately 35% of all approved drug targets but remain largely undrugged. Superluminal's platform creates candidate-ready compounds with unprecedented speed by leveraging deep biology and chemistry expertise, machine learning algorithms, and proprietary big data infrastructure. The company has secured significant funding, including a $120 million Series A round led by RA Capital Management, and has established strategic collaborations with pharmaceutical giant Eli Lilly & Company, with potential deal values up to $1.3 billion. Superluminal is advancing multiple small molecule programs focused on cardiometabolic diseases and obesity, with its lead program targeting rare genetic forms of obesity expected to enter clinical development in 2026.